Doxacurium
Grundinformationen
- CAS
106791-39-3- Standard-SMILES
COc1cc(CC2c3c(cc(OC)c(OC)c3OC)CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCc3cc(OC)c(OC)c(OC)c3C2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC- InChIKey
GBLRQXKSCRCLBZ-UHFFFAOYSA-N- Summenformel
- C56H78N2O16+2
- Durchschnittliche Molmasse
- 1.035,2 g/mol
- Monoisotopische Masse
- 1.034,5351344
Überblick
Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.
Namen und Bezeichner
- Bevorzugter Name
- Doxacurium
- IUPAC
- bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate
Namen und Synonyme
DoxacuriumDoxacurium ionDoxacurium cationbis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate133814-18-3DTXSID401019852P40015Y3WWbis(3-(6,7,8-trimethoxy-2-methyl-1-((3,4,5-trimethoxyphenyl)methyl)-3,4-dihydro-1H-isoquinolin-2-ium-2-yl)propyl) butanedioate7560511IZ6RefChem:590412CHEBI:4706BW-A-938U
Weitere Namen anzeigen
DTXCID801508512Isoquinolinium, 2,2'-((1,4-dioxo-1,4-butanediyl)bis(oxy-3,1-propanediyl))bis(1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-((3,4,5-trimethoxyphenyl)methyl))-8A4O17EP8T106791-39-3Isoquinolinium, 2,2'-[(1,4-dioxo-1,4-butanediyl)bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, (1R,1'S,2S,2'R)-rel-C07549CHEMBL1237123SCHEMBL10119676
Datenbank-Bezeichner
- CAS
106791-39-3、106819-53-8、133814-18-3- PubChem CID
- 60169
- ChEMBL
CHEMBL1237123
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 7,4
- Polarare Oberfläche (TPSA)
- 163 Ų
- H-Brücken-Donoren
- 0
- H-Brücken-Akzeptoren
- 16
- Frei drehbare Bindungen
- 29
- Schwere Atome
- 74
- Formalladung
- 2
- Komplexität
- 1.540
Experimentelle und physikochemische Eigenschaften
Solubility9.02e-05 g/L
Physical DescriptionSolid
Chemie und Industrie
Pharmakologische Informationen
Protein BindingApproximately 30%.
Pharmacodynamics
Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant. The neuromuscular block produced by doxacurium chloride may be antagonized by anticholinesterase agents. As with other nondepolarizing neuromuscular blocking agents, the more profound the neuromuscular block at reversal, the longer the time and the greater the dose of anticholinesterase required for recovery of neuromuscular function. Doxacurium chloride is approximately 2.5 to 3 times more potent than pancuronium and 10 to 12 times more potent than metocurine.
Mechanism of Action
Doxacurium chloride binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission (non-depolarizing). This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine.
Biological Half-Life99 minutes in normal healthy adults.
Metabolism/MetabolitesIn vivo data from humans suggest that doxacurium chloride is not metabolized and that the major elimination pathway is excretion of unchanged drug in urine and bile.
MeSH Pharmacological Classification
Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants.
Absorption, Distribution and Excretion
In vivo data from humans suggest that NUROMAX is not metabolized and that the major elimination pathway is excretion of unchanged drug in urine and bile.
0.11-0.43 L/kg [Healthy Young Adult Patients]
2.66 mL/min/kg [Healthy Young Adult Patients]
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…